{
    "symbol": "COLL",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-10 22:45:07",
    "content": " You are cautioned that such forward-looking statements involve risks and uncertainties, including and without limitation, the risks that we may not be able to derive the expected benefits of our recently completed acquisition of BioDelivery Sciences International, on the proposed schedule or at all, that we may not be able to successfully renegotiate our contracts related to Xtampza ER prescriptions on desired terms, that we may not be able to successfully commercialize our products and that we may incur significant expense and may not prevail in current or future patent infringement litigation or other litigation pertaining to our products. We are focused on growing the topline, accelerating the bottom-line, strategically deploying capital to create shareholder value, and renegotiating Xtampza ER contracts to achieve gross to net impact of less than 65% beginning in January 2023. Total net product revenues for the quarter were $83.8 million, down 4.5% over the $87.7 million in the first quarter of 2021. Adjusted operating expenses, which excludes stock-based compensation and acquisition-related expenses, were $25.2 million, down 8.4% compared to $27.5 million in the first quarter of 2021. Non-GAAP adjusted EBITDA was $43.5 million in the first quarter, down 4% compared to $45.3 million in the first quarter of 2021. For the full year, we expect total product revenues in the range of $450 million to $465 million, up approximately 65% at the midpoint compared to net product revenue of $276.9 million in 2021. Compared to the first quarter of 2021, Belbuca total prescriptions were up 4% and share of the branded ER market was up two percentage points to 17.4%. Compared to the first quarter of 2021, Xtampza ER prescriptions were up 3% and oxycodone ER market share grew to 34.2%, up 3.6 percentage points."
}